Anthony Mak Appointed Chief Executive Officer of Celsion China Ltd
Mr. Mak has over 20 years of experience in the medical products and health care industries in China and Asia Pacific. Most recently, he served as CEO of Oculus Ltd., a Singapore-listed regional optical company. Prior to that Mr. Mak held increasingly senior positions within Allergan, ultimately becoming Vice President and Managing Director for East Asia and building Allergan into a leading eye-care company in the region. Mr. Mak also has held management positions with Johnson & Johnson, G.D. Searle and Upjohn.
Dr. Augustine Cheung, Founder and Chief Executive Officer of Celsion Corporation, commented, "We are delighted that Anthony has joined the Celsion China team. We expect that his extensive experience with medical products in China and the Asia Pacific region will be most valuable in facilitating approval for Celsion's Prolieve product in the People's Republic of China and in preparing the way for Celsion to extend its product line in China."
ABOUT CELSION: Celsion Corporation, based in Columbia, Maryland, is a biotechnology company dedicated to the development and commercialization of treatment systems for cancer and other diseases using focused-heat energy, either administered alone, or in combination with other therapeutic devices, heat activated genes and heat activated drugs.
Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: http://www.celsion.com/.
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
CONTACT: Celsion Corporation, Columbia
Tony Deasey, 410-290-5390
tony@celsion.com
SOURCE: Celsion Corporation
